Stay updated with breaking news from Scott Berkheiser. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The first drug shown to slow Alzheimer’s disease hit the U.S. market over a year ago, but sales have lagged, major hospital systems have taken months to start using it and some insurers have rejected ...
The first drug shown to slow Alzheimer’s disease hit the U.S. market over a year ago, but sales have lagged, major hospital systems have taken months to start using it
The Food and Drug Administration gave Leqembi full approval last summer for patients with early stages of the disease. But sales have lagged.
The first drug shown to slow Alzheimer’s disease hit the US market over a year ago, but sales have lagged, major hospital systems have taken months to start using it and some insurers have rejected coverage. Doctors also expect some patients will hesitate to take Leqembi due to its limited…
The first drug shown to slow Alzheimer’s hit the U.S. market over a year ago, but sales have lagged and diagnosis and treatment remain complicated. Major hospital systems have taken